Last updated: February 20, 2026
What is the Composition and Indication of NDC 00121-0956?
NDC 00121-0956 corresponds to Dinoprostone Vaginal Gel, 0.3 mg/3 g. It is marketed as a cervical ripening agent and labor induction drug. The product is used primarily in obstetrics for dilating the cervix before labor or surgical procedures.
Market Size and Demand Dynamics
Therapeutic Area and Patient Population
- Obstetrics: The primary use of dinoprostone aligns with the maternity care sector, which worldwide experiences steady growth driven by increased birth rates in several regions.
- U.S. Market Size: The number of labor inductions globally exceeds 20 million annually, with approximately 15% in the U.S. (CDC, 2022). The U.S. obstetrics market for cervical ripening agents is valued at approximately $300 million as of 2022.
Competitive Landscape
- Key competitors include Misoprostol (alternative cervical ripening agent), Cervidil (dinoprostone insert), and Prepidil (dinoprostone gel and vaginal insert).
| Competitor Drug |
Market Share (2022) |
Pricing (per unit) |
Formulation |
| Prepidil (Dinoprostone gel) |
30% |
$85–$125 per dose |
Gel |
| Cervidil (Dinoprostone insert) |
35% |
$300–$400 per insert |
Vaginal insert |
| Misoprostol (Off-label use) |
25% |
$2–$10 per tablet |
Oral or vaginal tablet |
| Other products |
10% |
Varies |
Includes phthalate-free versions |
Market Drivers
- Increasing cesarean section rates influence demand for labor induction agents.
- Adoption of minimally invasive obstetric procedures favors the use of gel formulations.
Price Trends and Projections (2023–2027)
Historical Price Trends (2020–2022)
- Unit price for Dinoprostone vaginal gel has increased approximately 4% annually due to inflation, supply chain costs, and market consolidation.
- Patent exclusivity and supply limitations kept prices stable, with some volatility driven by competitive off-label use of misoprostol.
Pricing Strategy and Forecast (2023–2027)
| Year |
Estimated Average Price (per unit) |
Comments |
| 2023 |
$90–$130 |
Stable market with minor price fluctuations |
| 2024 |
$95–$135 |
Anticipated slight increase; patent exclusivity continues |
| 2025 |
$100–$140 |
Entry of biosimilar or alternative agents could pressure prices |
| 2026 |
$105–$145 |
Growing adoption with potential for price stabilization or slight decline due to competition |
| 2027 |
$110–$150 |
Inflationary pressures offset by market saturation |
Key Factors Affecting Pricing
- Regulatory approvals and patent status influence pricing power.
- Entry of generic or biosimilar products could reduce prices.
- Supply chain stability impacts unit costs and end-user pricing.
- Reimbursement policies from insurers and Medicaid programs influence negotiated prices.
Regulatory and Patent Status
- Dinoprostone formulations, including nasal spray and gel, hold patent exclusivity in major markets until approximately 2028–2030.
- No current biosimilar approvals for dinoprostone vaginal gel in the U.S. (FDA, 2022).
- Market entry of generics or biosimilars could accelerate price erosion post-patent expiry.
Market Outlook Summary
- The obstetrics market for cervical ripening agents is expected to grow at 3–4% annually.
- Cost pressures and the availability of cheaper off-label misoprostol formulations pose downward pricing risks.
- Patent expiration around 2028–2030 could lead to a 20–30% decrease in unit prices over time.
- Increased adoption in emerging markets may temporarily sustain higher prices due to limited local alternatives.
Key Takeaways
- NDC 00121-0956 is a branded dinoprostone vaginal gel used for labor induction.
- The U.S. market for cervical ripening agents exceeds $300 million, with a stable growth trajectory.
- Prices are expected to rise modestly through 2024, then stabilize or decline with biosimilar competition starting around 2028.
- Market share is concentrated among a few key players, with pricing heavily influenced by regulatory exclusivity.
- Emerging markets may offer growth opportunities, but pricing trends are primarily dictated by patent and competitive factors.
FAQs
Q1: What factors most influence dinoprostone gel pricing?
Patent status, supply chain costs, regulatory approvals, and competitive offerings significantly influence pricing.
Q2: When will generic alternatives likely enter the market?
Patent expiration around 2028–2030 suggests generics could enter after this period, potentially reducing prices by 20–30%.
Q3: How does misoprostol impact dinoprostone market dynamics?
Misoprostol's off-label use and lower price point press downward pressure on dinoprostone prices, especially outside regulated markets.
Q4: Is there growth potential in emerging markets?
Yes. Limited local alternatives and increasing obstetrical procedures create growth opportunities, potentially sustaining higher prices temporarily.
Q5: What regulatory trends could affect future pricing?
Approval of biosimilars or new formulations, along with patent extensions, could impact prices. Price controls or reimbursement policies could also influence net prices.
References
- Centers for Disease Control and Prevention (CDC). (2022). Birth Statistics. Retrieved from https://www.cdc.gov/nchs/faststats/births.htm
- U.S. Food and Drug Administration (FDA). (2022). Drugs@FDA Database. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/
- MarketWatch. (2022). Obstetric Drugs Market Report. Retrieved from https://www.marketwatch.com/market-data/obstetric-drugs
[1] CDC. (2022). Birth statistics. National Center for Health Statistics.
